代谢表型与心血管疾病:流行病学证据综述
本文综述了代谢表型分析的主要方法、流行病学数据分析步骤及挑战,并讨论了代谢物与冠心病和卒中的关联证据。研究提示心血管疾病具有系统性特征,涉及肠道微生物共代谢、支链氨基酸、甘油磷脂和胆固醇代谢及炎症过程等通路。代谢生物标志物在健康人群心血管风险分层中的临床效用尚未确立。
要点
- 代谢表型分析可揭示心血管疾病的系统性代谢通路特征。
- 代谢组与基因组数据整合可提供因果推断证据。
- 代谢生物标志物在健康人群风险分层中的临床效用尚未确立。
核心结论
- 代谢表型分析是表征心血管疾病分子特征的有力工具,有望带来新的机制理解、疗法及风险预测改进,但临床重要改善仍面临挑战。
研究设计与样本
- 本文为综述,总结了代谢表型分析的主要方法、流行病学分析步骤及相关挑战,并讨论了流行病学研究证据。
主要发现
- 流行病学研究将代谢物与冠心病和卒中相关联,提示心血管疾病的系统性特征。
- 识别出的相关代谢通路包括肠道微生物共代谢、支链氨基酸、甘油磷脂和胆固醇代谢以及炎症过程激活。
- 代谢组与基因组数据整合可通过孟德尔随机化为涉及的生化通路和潜在因果性提供新证据。
临床怎么用
- 代谢生物标志物用于健康个体心血管风险分层的临床效用尚未确立。
局限性
- 代谢生物标志物在健康人群风险分层中的临床效用尚未确立。
- 将代谢表型分析转化为临床重要改善仍面临挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolomics, the comprehensive measurement of low-molecular-weight molecules in biological fluids used for metabolic phenotyping, has emerged as a promising tool to better understand pathways underlying cardiovascular disease (CVD) and to improve cardiovascular risk stratification. Here, we present the main methodologies for metabolic phenotyping, the methodological steps to analyse these data in epidemiological settings and the associated challenges. We discuss evidence from epidemiological studies linking metabolites to coronary heart disease and stroke. These studies indicate the systemic nature of CVD and identify associated metabolic pathways such as gut microbial cometabolism, branched-chain amino acids, glycerophospholipid and cholesterol metabolism, as well as activation of inflammatory processes. Integration of metabolomic with genomic data can provide new evidence for involved biochemical pathways and potential for causality using Mendelian randomisation. The clinical utility of metabolic biomarkers for cardiovascular risk stratification in healthy individuals has not yet been established. As sample sizes with high-dimensional molecular data increase in epidemiological settings, integration of metabolomic data across studies and platforms with other molecular data will lead to new understanding of the metabolic processes underlying CVD and contribute to identification of potentially novel preventive and pharmacological targets. Metabolic phenotyping offers a powerful tool in the characterisation of the molecular signatures of CVD, paving the way to new mechanistic understanding and therapies, as well as improving risk prediction of CVD patients. However, there are still challenges to face in order to contribute to clinically important improvements in CVD.
引用
- Iliou A, Mikros E, Karaman I, et al. Metabolic phenotyping and cardiovascular disease: an overview of evidence from epidemiological settings. Heart. 2021. PMID: 33608305. doi:10.1136/heartjnl-2019-315615
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。